Identification

Name
Reserpine
Accession Number
DB00206  (APRD00472)
Type
Small Molecule
Groups
Approved, Investigational
Description

An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. [PubChem]

Structure
Thumb
Synonyms
  • (-)-Reserpine
  • (−)-reserpine
  • (3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester
  • 3,4,5-trimethoxybenzoyl methyl reserpate
  • Apoplon
  • Reserpin
  • Reserpine
  • Serpalan
External IDs
ENT-50146 / NSC-237659 / NSC-59272
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-reserpine Tab 0.25mgTablet.25 mgOralNovopharm Limited1967-12-312005-08-10Canada
ReserpineTablet.1 mg/1OralEon Labs, Inc.1988-03-112017-05-19Us
ReserpineTablet.25 mg/1OralEon Labs, Inc.1988-03-112017-05-19Us
Serpasil 0.25mgTablet0.25 mgOralNovartis1954-12-311999-08-04Canada
International/Other Brands
Apoplon / Hiserpia / Novoreserpine / Reserfia / Serpalan / Serpanray / Serpasil
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Hydropres 25 TabReserpine (.125 mg) + Hydrochlorothiazide (25 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312000-06-14Canada
Hydropres 50 TabReserpine (.125 mg) + Hydrochlorothiazide (50 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-311998-08-14Canada
Ser-AP-ES TabReserpine (0.1 mg) + Hydralazine hydrochloride (25 mg) + Hydrochlorothiazide (15 mg)TabletOralNovartis1960-12-312000-08-02Canada
Categories
UNII
8B1QWR724A
CAS number
50-55-5
Weight
Average: 608.6787
Monoisotopic: 608.273380888
Chemical Formula
C33H40N2O9
InChI Key
QEVHRUUCFGRFIF-MDEJGZGSSA-N
InChI
InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1
IUPAC Name
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
SMILES
[H][[email protected]]12C[[email protected]@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[[email protected]](OC)[[email protected]@H](C(=O)OC)[[email protected]@]1([H])C[[email protected]@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2

Pharmacology

Indication

Foe the treatment of hypertension

Structured Indications
Pharmacodynamics

Reserpine is an adrenergic blocking agent used to treat mild to moderate hypertension via the disruption of norepinephrine vesicular storage. The antihypertensive actions of Reserpine are a result of its ability to deplete catecholamines from peripheral sympathetic nerve endings. These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral resistance.

Mechanism of action

Reserpine's mechanism of action is through inhibition of the ATP/Mg2+ pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines.

TargetActionsOrganism
ASynaptic vesicular amine transporter
inhibitor
Human
UChromaffin granule amine transporterNot AvailableHuman
UBaculoviral IAP repeat-containing protein 5Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

62%

Metabolism
Not Available
Route of elimination

Reserpine is extensively metabolized to inactive compounds. It is slowly excreted via the urine and feces.

Half life
Not Available
Clearance
Not Available
Toxicity

Possible human carcinogen. May cause reproductive harm. ORL-RAT LD50 420 mg/kg; IPR-RAT LD50 44 mg/kg; IVN-RAT LD50 15 mg/kg; ORL-MUS LD50 200 mg/kg; SCU-MUS LD50 52 mg/kg; IPR-RBT LD50 7 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineReserpine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineReserpine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineReserpine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Reserpine.Experimental
AcebutololReserpine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Reserpine.Approved
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Reserpine.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Reserpine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Reserpine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Reserpine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Reserpine is combined with Alaproclate.Experimental
AlbendazoleThe serum concentration of Reserpine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Reserpine.Experimental, Investigational
AlectinibThe serum concentration of Reserpine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Reserpine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Reserpine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Reserpine is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Reserpine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Reserpine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Reserpine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Reserpine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololReserpine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Reserpine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Reserpine.Approved, Investigational
AmifostineReserpine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Reserpine is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Reserpine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Reserpine can be decreased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Reserpine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Reserpine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Reserpine is combined with Amperozide.Experimental
AmphetamineReserpine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Reserpine.Approved, Investigational
AmprenavirThe serum concentration of Reserpine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Reserpine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Reserpine is combined with Amyl Nitrite.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Reserpine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Reserpine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Reserpine.Approved, Investigational
ArotinololReserpine may increase the hypotensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Reserpine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Asenapine.Approved
AstemizoleThe serum concentration of Reserpine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Reserpine.Approved, Investigational
AtenololReserpine may increase the hypotensive activities of Atenolol.Approved
AtorvastatinThe serum concentration of Reserpine can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Reserpine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Azaperone.Investigational, Vet Approved
AzelastineReserpine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Reserpine is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Reserpine can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Reserpine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Reserpine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Reserpine.Approved
BefunololReserpine may increase the hypotensive activities of Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Reserpine.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Reserpine is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Reserpine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Reserpine is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Reserpine can be increased when it is combined with Benzocaine.Approved
BenzphetamineReserpine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Reserpine is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Reserpine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Reserpine.Approved, Vet Approved
BetaxololReserpine may increase the hypotensive activities of Betaxolol.Approved
BethanidineReserpine may increase the hypotensive activities of Bethanidine.Approved
BevantololReserpine may increase the hypotensive activities of Bevantolol.Approved
BietaserpineReserpine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostReserpine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Reserpine can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololReserpine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Reserpine.Approved, Withdrawn
BopindololReserpine may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Reserpine.Approved, Investigational
BosentanReserpine may increase the hypotensive activities of Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Reserpine.Approved
BQ-123Reserpine may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Reserpine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Reserpine is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Reserpine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Reserpine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Reserpine is combined with Bromisoval.Experimental
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Reserpine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Reserpine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Reserpine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololReserpine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolReserpine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Reserpine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bupivacaine.Approved, Investigational
BupranololReserpine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineReserpine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Reserpine can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Reserpine can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Butabarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Reserpine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Reserpine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Reserpine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Reserpine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Reserpine.Approved
CadralazineReserpine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineReserpine may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Reserpine.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Reserpine.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Reserpine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Reserpine is combined with Candesartan.Approved
CandoxatrilReserpine may increase the hypotensive activities of Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Reserpine is combined with Canertinib.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Reserpine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Reserpine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Reserpine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Reserpine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Reserpine.Withdrawn
CarteololReserpine may increase the hypotensive activities of Carteolol.Approved
CarvedilolReserpine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Reserpine can be increased when it is combined with Caspofungin.Approved
CeliprololReserpine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Reserpine.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Reserpine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Reserpine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Reserpine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorphenamine.Approved
ChlorphentermineReserpine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Reserpine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Reserpine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Reserpine can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Reserpine can be increased when it is combined with Cholesterol.Experimental, Investigational
Cholic AcidReserpine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CicletanineReserpine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Reserpine.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Reserpine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Reserpine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Reserpine.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Reserpine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Reserpine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Reserpine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Reserpine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Reserpine.Approved, Investigational
ClofazimineThe serum concentration of Reserpine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Reserpine.Approved, Investigational
ClomipramineThe serum concentration of Reserpine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Reserpine is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Reserpine.Approved, Nutraceutical
CloranololReserpine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Reserpine is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Reserpine can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Reserpine.Approved
CobicistatThe serum concentration of Reserpine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Reserpine.Approved
CocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Reserpine is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Reserpine.Approved
ColforsinThe serum concentration of Reserpine can be increased when it is combined with Colforsin.Experimental, Investigational
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Reserpine.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Reserpine.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Reserpine.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Reserpine.Approved
CryptenamineReserpine may increase the hypotensive activities of Cryptenamine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyclobenzaprine.Approved
CyclopenthiazideReserpine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe serum concentration of Reserpine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Reserpine.Approved, Investigational, Vet Approved
CyclothiazideReserpine may increase the hypotensive activities of Cyclothiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Reserpine is combined with Cymarin.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reserpine.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Reserpine.Approved
DaclatasvirThe serum concentration of Reserpine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Reserpine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Reserpine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapoxetine.Investigational
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Reserpine.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Reserpine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Reserpine.Approved, Investigational
DelaprilReserpine may increase the hypotensive activities of Delapril.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Reserpine is combined with Deramciclane.Investigational
DeserpidineReserpine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Desflurane.Approved
DesipramineThe serum concentration of Reserpine can be increased when it is combined with Desipramine.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Reserpine is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Reserpine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Reserpine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Reserpine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineReserpine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Reserpine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Reserpine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Reserpine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dezocine.Approved, Investigational
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Reserpine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Reserpine.Approved
DiclofenacThe serum concentration of Reserpine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Reserpine is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Reserpine is combined with Diethyl ether.Experimental
diethylnorspermineReserpine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionReserpine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Reserpine.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Difenoxin.Approved, Illicit
DigitoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Digoxin.Approved
DihydralazineReserpine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Reserpine can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Reserpine.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Reserpine is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Reserpine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Reserpine is combined with Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Reserpine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Reserpine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dixyrazine.Experimental
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Reserpine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Reserpine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Reserpine is combined with Doramectin.Vet Approved
DorzolamideReserpine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Reserpine is combined with Doxazosin.Approved
DoxepinThe serum concentration of Reserpine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Reserpine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Reserpine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Reserpine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Illicit
DronedaroneThe serum concentration of Reserpine can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Reserpine is combined with Drotebanol.Experimental, Illicit
DuloxetineReserpine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Reserpine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Reserpine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Reserpine is combined with Efavirenz.Approved, Investigational
EfonidipineReserpine may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Reserpine.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Reserpine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Enalapril.Approved, Vet Approved
EnalaprilatReserpine may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Reserpine.Approved
EndralazineReserpine may increase the hypotensive activities of Endralazine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Reserpine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Reserpine can be increased when it is combined with Enzalutamide.Approved
EpanololReserpine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Reserpine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Eplerenone.Approved
EpoprostenolReserpine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Reserpine is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Reserpine.Approved
ErgonovineThe serum concentration of Reserpine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Reserpine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Reserpine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Reserpine.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Reserpine.Approved, Investigational
EsmololReserpine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Reserpine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Reserpine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Reserpine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Reserpine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Reserpine is combined with Etacrynic acid.Approved
EthanolReserpine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Reserpine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Reserpine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Reserpine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Reserpine can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Reserpine.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Reserpine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Reserpine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamReserpine may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe serum concentration of Reserpine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferulic acidReserpine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Reserpine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Reserpine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Reserpine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Reserpine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Reserpine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Reserpine can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe serum concentration of Reserpine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Reserpine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Reserpine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Reserpine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluspirilene.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Reserpine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Reserpine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Reserpine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Reserpine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Reserpine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Reserpine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Reserpine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Reserpine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Reserpine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Reserpine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Reserpine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Reserpine.Approved
GenisteinThe serum concentration of Reserpine can be increased when it is combined with Genistein.Investigational
GepefrineReserpine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Reserpine is combined with Gepirone.Investigational
GitoformateThe risk or severity of adverse effects can be increased when Reserpine is combined with Gitoformate.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Reserpine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Reserpine is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Reserpine can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Reserpine can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Reserpine can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Reserpine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Reserpine.Investigational, Withdrawn
GuanabenzReserpine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelReserpine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineReserpine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineReserpine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Reserpine is combined with Guanfacine.Approved, Investigational
GuanoclorReserpine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzReserpine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanReserpine may increase the hypotensive activities of Guanoxan.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Reserpine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Reserpine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Reserpine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Reserpine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumReserpine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Reserpine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneReserpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Reserpine.Approved, Vet Approved
HydroflumethiazideReserpine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineReserpine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Reserpine.Approved
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Reserpine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Reserpine.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Reserpine.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Reserpine.Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Reserpine.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Reserpine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Reserpine is combined with Indapamide.Approved
IndenololReserpine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Reserpine can be decreased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Reserpine is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Reserpine.Approved, Investigational
IndoraminReserpine may increase the hypotensive activities of Indoramin.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Reserpine.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Reserpine.Approved, Investigational
Iofetamine I-123Reserpine may decrease the stimulatory activities of Iofetamine I-123.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Reserpine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Reserpine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Reserpine is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Reserpine.Approved, Investigational
IsavuconazoniumThe serum concentration of Reserpine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Reserpine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Reserpine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Reserpine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Reserpine.Approved, Vet Approved
KetamineThe serum concentration of Reserpine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinReserpine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Reserpine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Reserpine.Approved, Investigational
LabetalolReserpine may increase the hypotensive activities of Labetalol.Approved
LacidipineReserpine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Reserpine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Reserpine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Reserpine is combined with Lanatoside C.Experimental
LandiololReserpine may increase the hypotensive activities of Landiolol.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Reserpine.Approved, Investigational
LapatinibThe serum concentration of Reserpine can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostReserpine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Reserpine.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Reserpine.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Reserpine.Approved
LercanidipineReserpine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Reserpine.Approved, Investigational
LevobunololReserpine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levocetirizine.Approved
LevodopaReserpine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Reserpine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Reserpine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Reserpine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Reserpine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Reserpine.Approved, Investigational
LevothyroxineThe serum concentration of Reserpine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Reserpine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Reserpine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Reserpine.Approved, Investigational
LinsidomineReserpine may increase the hypotensive activities of Linsidomine.Experimental
LiothyronineThe serum concentration of Reserpine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Reserpine can be decreased when it is combined with Liotrix.Approved
LisdexamfetamineReserpine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Reserpine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Lofentanil.Illicit
LofexidineReserpine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Reserpine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Reserpine.Approved
LopinavirThe serum concentration of Reserpine can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Loprazolam.Experimental
LoratadineThe serum concentration of Reserpine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Reserpine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Reserpine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Reserpine is combined with Losartan.Approved
LovastatinThe serum concentration of Reserpine can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Loxapine.Approved
LumacaftorThe serum concentration of Reserpine can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone.Approved
MacitentanReserpine may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Vet Approved
ManidipineReserpine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Reserpine is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Reserpine can be increased when it is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Reserpine.Withdrawn
MebendazoleThe serum concentration of Reserpine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Reserpine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Reserpine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Reserpine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Reserpine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Reserpine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Melperone.Approved, Investigational
MephedroneReserpine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineReserpine may decrease the stimulatory activities of Mephentermine.Approved
MepindololReserpine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Reserpine can be increased when it is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Reserpine is combined with Meptazinol.Experimental
MequitazineReserpine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Metaxalone.Approved
MethadoneThe serum concentration of Reserpine can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Reserpine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineReserpine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Reserpine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Reserpine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Reserpine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Methohexital.Approved
MethoserpidineReserpine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Reserpine.Approved
MethotrimeprazineReserpine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineReserpine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Reserpine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Reserpine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Reserpine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylecgonine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Reserpine.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Reserpine.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Metildigoxin.Experimental
MetipranololReserpine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Reserpine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Metolazone.Approved
MetoprololReserpine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineReserpine may increase the sedative activities of Metyrosine.Approved
MibefradilThe serum concentration of Reserpine can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Reserpine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Reserpine.Approved, Illicit
MidomafetamineReserpine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Reserpine can be decreased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Reserpine.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Reserpine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Reserpine is combined with Minoxidil.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Reserpine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Reserpine.Investigational
MirtazapineReserpine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Reserpine can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Reserpine.Approved, Investigational
MMDAReserpine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Reserpine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Molindone.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Reserpine.Approved, Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Reserpine.Approved, Investigational
MoxonidineReserpine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineReserpine may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Reserpine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Investigational
NadololReserpine may increase the hypotensive activities of Nadolol.Approved
NaftopidilReserpine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Reserpine.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Reserpine.Approved, Vet Approved
NaltrexoneThe serum concentration of Reserpine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Reserpine.Approved, Investigational
NaringeninThe serum concentration of Reserpine can be increased when it is combined with Naringenin.Experimental
NebivololThe risk or severity of adverse effects can be increased when Reserpine is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Reserpine can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Reserpine can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Reserpine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Reserpine is combined with Nesiritide.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Reserpine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Reserpine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nifedipine.Approved
NiguldipineReserpine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Reserpine.Approved, Investigational
NilvadipineReserpine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nimodipine.Approved
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Reserpine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Reserpine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Reserpine can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Reserpine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Reserpine.Approved
NorethisteroneThe serum concentration of Reserpine can be decreased when it is combined with Norethisterone.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nortriptyline.Approved
ObinutuzumabReserpine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Reserpine.Withdrawn
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Reserpine.Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Reserpine.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Reserpine is combined with Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Reserpine is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olopatadine.Approved
OmapatrilatReserpine may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Reserpine.Approved
OmeprazoleThe serum concentration of Reserpine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Reserpine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Reserpine is combined with Opium.Approved, Illicit
OrphenadrineReserpine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Reserpine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Reserpine.Approved
OuabainThe risk or severity of adverse effects can be increased when Reserpine is combined with Ouabain.Approved
OxazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxethazaine.Approved, Investigational
OxprenololReserpine may increase the hypotensive activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxymorphone.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Reserpine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Reserpine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Paliperidone.Approved
Palmitic AcidThe serum concentration of Reserpine can be increased when it is combined with Palmitic Acid.Approved, Experimental
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Reserpine.Approved, Investigational
PantoprazoleThe serum concentration of Reserpine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Reserpine is combined with Papaverine.Approved
ParaldehydeReserpine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Reserpine.Approved
ParoxetineThe serum concentration of Reserpine can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Reserpine.Approved
PenbutololReserpine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Reserpine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentobarbital.Approved, Vet Approved
PentoliniumReserpine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Reserpine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
PerazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Reserpine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perphenazine.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Reserpine is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Reserpine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Reserpine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Reserpine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Reserpine.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Reserpine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Phenoperidine.Experimental
PhenoxybenzamineReserpine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Reserpine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Reserpine.Withdrawn
PhentermineReserpine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineReserpine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Reserpine.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Reserpine.Approved
PimozideThe serum concentration of Reserpine can be increased when it is combined with Pimozide.Approved
PinacidilReserpine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololReserpine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Reserpine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Reserpine.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Reserpine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Reserpine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Reserpine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Reserpine can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideReserpine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Reserpine.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Reserpine.Approved
PosaconazoleThe serum concentration of Reserpine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololReserpine may increase the hypotensive activities of Practolol.Approved
PramipexoleReserpine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Reserpine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Reserpine is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Reserpine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Reserpine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Reserpine is combined with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Reserpine can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Reserpine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Reserpine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Reserpine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Reserpine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Reserpine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Reserpine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Propoxycaine.Approved
PropranololReserpine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProscillaridinThe risk or severity of adverse effects can be increased when Reserpine is combined with Proscillaridin.Experimental
ProtriptylineThe serum concentration of Reserpine can be increased when it is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Reserpine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Reserpine.Approved
PSD502The risk or severity of adverse effects can be increased when Reserpine is combined with PSD502.Investigational
PseudoephedrineReserpine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Reserpine can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Reserpine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Reserpine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Reserpine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Reserpine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Reserpine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Reserpine.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Reserpine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Reserpine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Reserpine.Approved
ReboxetineThe serum concentration of Reserpine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Reserpine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Remifentanil.Approved
RemikirenReserpine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Reserpine is combined with Remoxipride.Approved, Withdrawn
RescinnamineReserpine may increase the hypotensive activities of Rescinnamine.Approved
RifampicinThe serum concentration of Reserpine can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Reserpine.Approved, Investigational
RilmenidineReserpine may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Reserpine can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Reserpine is combined with Riociguat.Approved
RisperidoneReserpine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Reserpine is combined with Ritanserin.Investigational
RitobegronReserpine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Reserpine.Approved, Investigational
RituximabReserpine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Reserpine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Reserpine.Approved
RolapitantThe serum concentration of Reserpine can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Reserpine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Romifidine.Vet Approved
RopiniroleReserpine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ropivacaine.Approved
RotigotineReserpine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Reserpine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Reserpine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Reserpine.Withdrawn
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Reserpine.Approved, Vet Approved
SaprisartanReserpine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Reserpine can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Reserpine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Reserpine is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Reserpine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Reserpine.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Reserpine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Reserpine can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Reserpine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Reserpine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Reserpine.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Reserpine.Approved
SimvastatinThe serum concentration of Reserpine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Reserpine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Reserpine.Approved, Investigational
SitaxentanReserpine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Reserpine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Reserpine.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Reserpine.Approved, Investigational
SotalolReserpine may increase the hypotensive activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Reserpine.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Reserpine.Experimental
SpiraprilReserpine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Reserpine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StaurosporineThe serum concentration of Reserpine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Reserpine is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Reserpine.Approved, Investigational
StreptozocinThe serum concentration of Reserpine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Reserpine can be increased when it is combined with Sulfinpyrazone.Approved
SulpirideThe risk or severity of adverse effects can be increased when Reserpine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Reserpine is combined with Sultopride.Experimental
SumatriptanThe serum concentration of Reserpine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Reserpine can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantReserpine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Reserpine can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Reserpine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Reserpine.Approved, Investigational
TalinololReserpine may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Reserpine.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Reserpine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Reserpine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Reserpine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Reserpine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Reserpine.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Reserpine.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Reserpine.Approved, Withdrawn
TelmisartanThe risk or severity of adverse effects can be increased when Reserpine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Temazepam.Approved
TemocaprilReserpine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Reserpine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Reserpine is combined with Terazosin.Approved
TerfenadineThe serum concentration of Reserpine can be increased when it is combined with Terfenadine.Withdrawn
TerlipressinReserpine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TertatololReserpine may increase the hypotensive activities of Tertatolol.Experimental
TesmilifeneThe serum concentration of Reserpine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Reserpine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrodotoxin.Investigational
ThalidomideReserpine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineReserpine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Reserpine is combined with Tiapride.Approved, Investigational
TiboloneReserpine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Reserpine.Approved
TicrynafenReserpine may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tilidine.Experimental
TimololReserpine may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tizanidine.Approved
TolazolineReserpine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Reserpine is combined with Tolcapone.Approved, Withdrawn
TolonidineReserpine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Reserpine.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Reserpine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Reserpine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Reserpine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Reserpine is combined with Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Reserpine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Reserpine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Reserpine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Reserpine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reserpine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Reserpine.Approved
TravoprostReserpine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe serum concentration of Reserpine can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilReserpine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Reserpine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Reserpine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Reserpine is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Reserpine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideReserpine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Reserpine is combined with Trichloroethylene.Experimental
TrifluoperazineThe serum concentration of Reserpine can be increased when it is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Reserpine is combined with Trifluperidol.Experimental
TriflupromazineThe serum concentration of Reserpine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinReserpine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanReserpine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimethoprimThe serum concentration of Reserpine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Reserpine can be increased when it is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triprolidine.Approved
TroleandomycinThe serum concentration of Reserpine can be increased when it is combined with Troleandomycin.Approved
UdenafilUdenafil may increase the antihypertensive activities of Reserpine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Reserpine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Reserpine.Approved
UnoprostoneReserpine may increase the hypotensive activities of Unoprostone.Approved
UrapidilReserpine may increase the hypotensive activities of Urapidil.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Reserpine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Reserpine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Reserpine.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Reserpine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Reserpine.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Reserpine.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Reserpine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Reserpine is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Reserpine is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Reserpine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Reserpine.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Reserpine.Approved
VincamineReserpine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Reserpine.Approved, Investigational
VinorelbineThe serum concentration of Reserpine can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineReserpine may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Reserpine is combined with Vinyl ether.Experimental
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Reserpine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Reserpine is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Reserpine.Approved
XenonThe risk or severity of adverse effects can be increased when Reserpine is combined with Xenon.Experimental
XipamideReserpine may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Xylazine.Vet Approved
XylometazolineReserpine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Reserpine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Reserpine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Reserpine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Reserpine.Approved
ZimelidineThe serum concentration of Reserpine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Reserpine is combined with Ziprasidone.Approved
ZofenoprilReserpine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Reserpine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Reserpine.Approved, Investigational
ZolpidemReserpine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Reserpine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Reserpine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Reserpine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Magnesium, potassium and zinc needs increased.
  • Take with food to reduce irritation. Avoid alcohol.

References

General References
  1. Authors unspecified: Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979 Dec 7;242(23):2562-71. [PubMed:490882]
  2. Authors unspecified: Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967 Dec 11;202(11):1028-34. [PubMed:4862069]
  3. Authors unspecified: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991 Jun 26;265(24):3255-64. [PubMed:2046107]
  4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. Epub 2003 May 14. [PubMed:12748199]
  5. Moser M: "Cost containment" in the management of hypertension. Ann Intern Med. 1987 Jul;107(1):107-9. [PubMed:3592424]
External Links
Human Metabolome Database
HMDB14351
KEGG Drug
D00197
KEGG Compound
C06539
PubChem Compound
5770
PubChem Substance
46505863
ChemSpider
5566
BindingDB
50017712
ChEBI
28487
ChEMBL
CHEMBL772
Therapeutic Targets Database
DAP000755
PharmGKB
PA451236
Drugs.com
Drugs.com Drug Page
Wikipedia
Reserpine
ATC Codes
C02LA51 — Reserpine and diuretics, combinations with other drugsC02AA52 — Reserpine, combinationsC02LA71 — Reserpine and diuretics, combinations with psycholepticsC02LA01 — Reserpine and diureticsC02AA02 — Reserpine
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
1Unknown StatusTreatmentAmphetamine-Related Disorders1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases1
2CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders1
2RecruitingTreatmentRefractory Hypertension1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionCardiovascular Disease (CVD) / Cerebrovascular Disorders / Heart Diseases / Hypertensive1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Eli lilly and co
  • Bowman pharmaceuticals inc
  • Bristol myers squibb co
  • Barr laboratories inc
  • Bell pharmacal corp
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • Halsey drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Marshall pharmacal corp
  • Mk laboratories inc
  • Mylan pharmaceuticals inc
  • Pharmavite pharmaceuticals
  • Purepac pharmaceutical co
  • Private formulations inc
  • Rexall drug co
  • Roxane laboratories inc
  • Sandoz inc
  • Solvay pharmaceuticals
  • Tablicaps inc
  • Teva pharmaceuticals usa inc
  • Valeant pharmaceuticals international
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Lannett co inc
  • Panray corp sub ormont drug and chemical co inc
  • Vale chemical co inc
  • Vitarine pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral.25 mg
TabletOral.1 mg/1
TabletOral.25 mg/1
TabletOral
TabletOral0.25 mg
Prices
Unit descriptionCostUnit
Reserpine 0.25 mg tablet1.52USD tablet
Reserpine 0.1 mg tablet0.83USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)264.5 °CPhysProp
water solubility73 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.2Not Available
pKa6.6MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0113 mg/mLALOGPS
logP4.05ALOGPS
logP3.53ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)16.29ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area117.78 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity161.42 m3·mol-1ChemAxon
Polarizability66.05 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9216
Blood Brain Barrier+0.9257
Caco-2 permeable+0.6549
P-glycoprotein substrateSubstrate0.7928
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.75
Renal organic cation transporterInhibitor0.5194
CYP450 2C9 substrateNon-substrate0.8859
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7065
CYP450 1A2 substrateInhibitor0.8965
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9384
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7062
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9439
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1297 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7505
hERG inhibition (predictor II)Non-inhibitor0.6194
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.3 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-052b-0944108000-d2416a07c507dd693e2b
Mass Spectrum (Electron Ionization)MSsplash10-0002-2943000000-8f7998aa667566277f3f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0006-0000090000-a4f3a4e74644a66e8705
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0006-0000090000-22aa398156f73127b459
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0006-0000090000-1a35ce10a9657b978845
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0006-0000090000-f1a507980fe5d4bc47a4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0108920000-d8cec36e08efb0c1e16e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000009000-2bafaa3238dfda9f4989
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0916102000-d591ae99a68ca35e63b7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006t-0911000000-1cb6207a1835b7efb13a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0910000000-550f1f23f96cefe74849
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05gi-1910000000-9dd2d1b6087fe8b9d1c9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-1910000000-7038e3a2f74fff79f220
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000009000-ea7c0832701dc10b3266
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0916103000-b1128c59f469bc4d949f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006t-0911000000-8109e56a0558f3f60659
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0910000000-c3773763c7f72b03b234
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05gi-1910000000-21728d59759dc657e49b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-1910000000-bf727df9cb8b3d8296a0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0108920000-29c40cb6bef71c53750f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000009000-0004d3aa672941e611c5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000009000-523f001c9c32d1385552
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0101009000-69cc395149f9a4451b3f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0915103000-a4c1fb5ec768bc8c97cb
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006t-0912000000-cf0f8684c8b84f7e412e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000009000-c668164b87d533a8d8f3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000009000-ff4084f4af36b83b2568
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0002009000-f6df1d086abaff8888d5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052b-0319207000-0b0edf20dde921411913
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0539201000-768cf840a0a7d1abe7f6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0003910000-4557ca8877fd85a69ba8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0009810000-30ee17a44c90d99c4cf7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0007920000-e0f73b5fcd3ba69e3f41
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0107920000-9a797cdf56ac618b8436
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0107920000-20d36b2dee2d9984b454
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0117920000-0f76604f9bf51d86cd1f
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-01ot-0117946000-0613998d589b96bffcb8
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0002-0108944000-e6ce6049b8052a65fb14
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0002-0009832000-18eb565a7321f719807f
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0lei-6922345625-0ad422142580b61b19ef
MS/MS Spectrum - , positiveLC-MS/MSsplash10-08fs-1823119000-ee81332e154356c9dc3b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-2923100000-57ebb3f9ade6bbbee040

Taxonomy

Description
This compound belongs to the class of organic compounds known as yohimbine alkaloids. These are alkaloids containing the pentacyclic yohimban skeleton. The Yohimbinoid alkaloids contain a carbocyclic ring E arising through C-17 to C-18 bond formation in a corynantheine precursor.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Yohimbine alkaloids
Sub Class
Not Available
Direct Parent
Yohimbine alkaloids
Alternative Parents
Corynanthean-type alkaloids / Beta carbolines / Gallic acid and derivatives / M-methoxybenzoic acids and derivatives / P-methoxybenzoic acids and derivatives / 3-alkylindoles / Benzoic acid esters / Anisoles / Methoxybenzenes / Phenoxy compounds
show 16 more
Substituents
Yohimbine / Corynanthean skeleton / Yohimbine alkaloid / Pyridoindole / Beta-carboline / Gallic acid or derivatives / P-methoxybenzoic acid or derivatives / M-methoxybenzoic acid or derivatives / Benzoate ester / 3-alkylindole
show 36 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
alkaloid ester, yohimban alkaloid (CHEBI:28487) / Indole alkaloids, Alkaloids (C06539)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles...
Gene Name
SLC18A2
Uniprot ID
Q05940
Uniprot Name
Synaptic vesicular amine transporter
Molecular Weight
55712.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sievert MK, Hajipour AR, Ruoho AE: Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels. Anal Biochem. 2007 Aug 1;367(1):68-78. Epub 2007 May 3. [PubMed:17559790]
  4. Naudon L, Leroux-Nicollet I, Raisman-Vozari R, Botton D, Costentin J: Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex. Synapse. 1995 Sep;21(1):29-36. [PubMed:8525459]
  5. Erickson JD, Eiden LE, Hoffman BJ: Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10993-7. [PubMed:1438304]
  6. Mandela P, Chandley M, Xu YY, Zhu MY, Ordway GA: Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles. Neurochem Int. 2010 May-Jun;56(6-7):760-7. doi: 10.1016/j.neuint.2010.02.011. Epub 2010 Feb 20. [PubMed:20176067]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin transmembrane transporter activity
Specific Function
Involved in the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles of neuroendocrine and endocrine cells.
Gene Name
SLC18A1
Uniprot ID
P54219
Uniprot Name
Chromaffin granule amine transporter
Molecular Weight
56256.71 Da
References
  1. Ashe KM, Chiu WL, Khalifa AM, Nicolas AN, Brown BL, De Martino RR, Alexander CP, Waggener CT, Fischer-Stenger K, Stewart JK: Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain. Neuro Endocrinol Lett. 2011;32(3):253-8. [PubMed:21712771]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignmen...
Gene Name
BIRC5
Uniprot ID
O15392
Uniprot Name
Baculoviral IAP repeat-containing protein 5
Molecular Weight
16388.555 Da
References
  1. Wang Z, Guo X, Liu Z, Cui M, Song F, Liu S: Studies on alkaloids binding to GC-rich human survivin promoter DNA using positive and negative ion electrospray ionization mass spectrometry. J Mass Spectrom. 2008 Mar;43(3):327-35. [PubMed:17968851]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522]
  2. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  4. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
  5. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945]
  6. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153]
  7. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  8. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
  9. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994 Dec 8;372(6506):549-52. [PubMed:7990927]
Details
3. Bile salt export pump
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
  2. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schomig E: Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998 Nov 20;273(47):30915-20. [PubMed:9812985]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:34